| Product Code: ETC10765522 | Publication Date: Apr 2025 | Updated Date: Oct 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | No. of Pages: 65 | No. of Figures: 34 | No. of Tables: 19 | |
The Japan pemetrexed import market in 2024 continued to see a diverse range of sources, with top exporting countries being the USA, Germany, Ireland, Switzerland, and Sweden. Despite the variety of sources, market concentration, as measured by the Herfindahl-Hirschman Index (HHI), remained low. The market experienced a slight decline over the period 2020-2024, with a compound annual growth rate (CAGR) of -3.23%. The growth rate from 2023 to 2024 also showed a decrease of -2.99%, indicating a challenging environment for pemetrexed imports in Japan.

1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Japan Pemetrexed Market Overview |
3.1 Japan Country Macro Economic Indicators |
3.2 Japan Pemetrexed Market Revenues & Volume, 2021 & 2031F |
3.3 Japan Pemetrexed Market - Industry Life Cycle |
3.4 Japan Pemetrexed Market - Porter's Five Forces |
3.5 Japan Pemetrexed Market Revenues & Volume Share, By Indication, 2021 & 2031F |
3.6 Japan Pemetrexed Market Revenues & Volume Share, By Mechanism of Action, 2021 & 2031F |
3.7 Japan Pemetrexed Market Revenues & Volume Share, By Combination Therapy, 2021 & 2031F |
3.8 Japan Pemetrexed Market Revenues & Volume Share, By End User, 2021 & 2031F |
3.9 Japan Pemetrexed Market Revenues & Volume Share, By Administration Route, 2021 & 2031F |
4 Japan Pemetrexed Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of lung cancer in Japan |
4.2.2 Growing awareness about the benefits of pemetrexed in cancer treatment |
4.2.3 Advancements in healthcare infrastructure and access to cancer care services in Japan |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for drug approvals in Japan |
4.3.2 High cost associated with pemetrexed treatment |
4.3.3 Competition from alternative cancer treatment options |
5 Japan Pemetrexed Market Trends |
6 Japan Pemetrexed Market, By Types |
6.1 Japan Pemetrexed Market, By Indication |
6.1.1 Overview and Analysis |
6.1.2 Japan Pemetrexed Market Revenues & Volume, By Indication, 2021 - 2031F |
6.1.3 Japan Pemetrexed Market Revenues & Volume, By Non-Small Cell Lung Cancer, 2021 - 2031F |
6.1.4 Japan Pemetrexed Market Revenues & Volume, By Mesothelioma, 2021 - 2031F |
6.1.5 Japan Pemetrexed Market Revenues & Volume, By Breast Cancer, 2021 - 2031F |
6.1.6 Japan Pemetrexed Market Revenues & Volume, By Colorectal Cancer, 2021 - 2031F |
6.1.7 Japan Pemetrexed Market Revenues & Volume, By Pancreatic Cancer, 2021 - 2031F |
6.2 Japan Pemetrexed Market, By Mechanism of Action |
6.2.1 Overview and Analysis |
6.2.2 Japan Pemetrexed Market Revenues & Volume, By Antifolate, 2021 - 2031F |
6.2.3 Japan Pemetrexed Market Revenues & Volume, By DNA Synthesis Inhibition, 2021 - 2031F |
6.2.4 Japan Pemetrexed Market Revenues & Volume, By Enzyme Targeting, 2021 - 2031F |
6.2.5 Japan Pemetrexed Market Revenues & Volume, By Cell Growth Suppression, 2021 - 2031F |
6.2.6 Japan Pemetrexed Market Revenues & Volume, By Purine Synthesis Blockade, 2021 - 2031F |
6.3 Japan Pemetrexed Market, By Combination Therapy |
6.3.1 Overview and Analysis |
6.3.2 Japan Pemetrexed Market Revenues & Volume, By Platinum-Based Chemotherapy, 2021 - 2031F |
6.3.3 Japan Pemetrexed Market Revenues & Volume, By Immunotherapy, 2021 - 2031F |
6.3.4 Japan Pemetrexed Market Revenues & Volume, By Radiation Therapy, 2021 - 2031F |
6.3.5 Japan Pemetrexed Market Revenues & Volume, By Personalized Medicine, 2021 - 2031F |
6.3.6 Japan Pemetrexed Market Revenues & Volume, By Monoclonal Antibodies, 2021 - 2031F |
6.4 Japan Pemetrexed Market, By End User |
6.4.1 Overview and Analysis |
6.4.2 Japan Pemetrexed Market Revenues & Volume, By Hospitals, 2021 - 2031F |
6.4.3 Japan Pemetrexed Market Revenues & Volume, By Oncology Clinics, 2021 - 2031F |
6.4.4 Japan Pemetrexed Market Revenues & Volume, By Specialty Clinics, 2021 - 2031F |
6.4.5 Japan Pemetrexed Market Revenues & Volume, By Research Institutes, 2021 - 2031F |
6.4.6 Japan Pemetrexed Market Revenues & Volume, By Pharmaceutical Companies, 2021 - 2031F |
6.5 Japan Pemetrexed Market, By Administration Route |
6.5.1 Overview and Analysis |
6.5.2 Japan Pemetrexed Market Revenues & Volume, By Intravenous, 2021 - 2031F |
6.5.3 Japan Pemetrexed Market Revenues & Volume, By Injection, 2021 - 2031F |
6.5.4 Japan Pemetrexed Market Revenues & Volume, By IV Infusion, 2021 - 2031F |
6.5.5 Japan Pemetrexed Market Revenues & Volume, By Cancer Treatment Centers, 2021 - 2031F |
6.5.6 Japan Pemetrexed Market Revenues & Volume, By Hospital Pharmacy, 2021 - 2031F |
7 Japan Pemetrexed Market Import-Export Trade Statistics |
7.1 Japan Pemetrexed Market Export to Major Countries |
7.2 Japan Pemetrexed Market Imports from Major Countries |
8 Japan Pemetrexed Market Key Performance Indicators |
8.1 Number of clinical trials using pemetrexed in Japan |
8.2 Adoption rate of pemetrexed in different regions of Japan |
8.3 Patient satisfaction and outcomes post pemetrexed treatment |
9 Japan Pemetrexed Market - Opportunity Assessment |
9.1 Japan Pemetrexed Market Opportunity Assessment, By Indication, 2021 & 2031F |
9.2 Japan Pemetrexed Market Opportunity Assessment, By Mechanism of Action, 2021 & 2031F |
9.3 Japan Pemetrexed Market Opportunity Assessment, By Combination Therapy, 2021 & 2031F |
9.4 Japan Pemetrexed Market Opportunity Assessment, By End User, 2021 & 2031F |
9.5 Japan Pemetrexed Market Opportunity Assessment, By Administration Route, 2021 & 2031F |
10 Japan Pemetrexed Market - Competitive Landscape |
10.1 Japan Pemetrexed Market Revenue Share, By Companies, 2024 |
10.2 Japan Pemetrexed Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here